Full Press Release Details
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes.
LXRX
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes
Key Takeaway: Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes